Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

医学 Evolocumab公司 急性冠脉综合征 内科学 传统PCI 危险系数 经皮冠状动脉介入治疗 心肌梗塞 心脏病学 他汀类 不稳定型心绞痛 中止 回顾性队列研究 载脂蛋白B 胆固醇 置信区间 载脂蛋白A1
作者
Yahao Zhang,Yanghui Zhang,Bin Zhang,Zheng Chen,Yongjie Wei,Penglei Chen,Chao Chang,Guizhi Liu,Kui Chen,Jiandong Ding,Zhengming Jiang
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:44 (6): 901-912 被引量:8
标识
DOI:10.1016/j.clinthera.2022.04.010
摘要

Evolocumab has been shown to improve cardiovascular outcomes in patients with stable atherosclerotic disease. Whether this benefit persists in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remains undetermined. This study aimed to evaluate the efficacy and safety of the early initiation of evolocumab in Chinese patients with ACS undergoing PCI.This retrospective cohort study involved 1564 consecutive patients who had been hospitalized with ACS and underwent PCI, and who had elevated LDL-C levels (≥1.8 mmol/L after receiving high-intensity statin therapy for ≥4 weeks; ≥2.3 mmol/L after receiving low- or moderate-intensity statin; or ≥3.2 mmol/L without statin therapy). Patients who received evolocumab (initiated in-hospital and after 18 months) were included in the evolocumab group (n = 414), and all other patients were included in the control group (n = 1150). The primary outcome at 18 months was a composite of ischemic stroke, cardiovascular death, myocardial infarction, hospitalization for unstable angina, or coronary revascularization. The evolocumab treatment effect on the primary outcome was assessed in all prespecified subgroups.At 18 months, evolocumab combined with statins reduced LDL-C levels from baseline levels by 42.48% compared with statins alone. After multivariable adjustment, evolocumab combined with statins significantly reduced the primary outcome (8.2% vs 12.4%; adjusted hazard ratio, 0.65; 95% CI, 0.45-0.95; P = 0.025). In addition, evolocumab consistently reduced the primary outcome across the major subgroups. For the safety outcomes, no significant differences between the groups were observed in any adverse events.Among Chinese patients who underwent PCI for ACS, the early initiation of evolocumab combined with statin treatment effectively reduced LDL-C levels and lowered the incidence of recurrent ischemic cardiovascular events, with satisfactory tolerability and safety. Chinese Clinical Trial Registry identifier: ChiCTR2100049364.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱吃泡芙完成签到,获得积分10
1秒前
白桃战士完成签到,获得积分10
2秒前
4秒前
qingchenwuhou完成签到 ,获得积分10
4秒前
XXX完成签到,获得积分10
5秒前
锡嘻完成签到 ,获得积分10
5秒前
6秒前
彗星入梦完成签到 ,获得积分10
6秒前
恋恋青葡萄完成签到,获得积分10
6秒前
隐形万言完成签到,获得积分10
8秒前
Time完成签到,获得积分10
8秒前
土木研学僧完成签到,获得积分10
9秒前
yjy完成签到 ,获得积分10
9秒前
A溶大美噶完成签到,获得积分10
9秒前
yar应助萨尔莫斯采纳,获得10
10秒前
Will发布了新的文献求助10
10秒前
美好的鹏笑完成签到,获得积分10
12秒前
啦啦啦啦啦完成签到,获得积分10
12秒前
LYegoist完成签到,获得积分10
14秒前
可爱的小丸子完成签到,获得积分10
14秒前
一川烟叶完成签到,获得积分10
16秒前
16秒前
19秒前
iFan完成签到 ,获得积分10
19秒前
萨尔莫斯完成签到,获得积分10
19秒前
合适靖儿完成签到 ,获得积分10
21秒前
林林林完成签到,获得积分10
22秒前
斯琪欣完成签到,获得积分10
23秒前
24秒前
MQQ完成签到 ,获得积分10
24秒前
meng发布了新的文献求助10
24秒前
25秒前
zxc167完成签到,获得积分10
25秒前
研友_nVWP2Z完成签到 ,获得积分10
27秒前
俭朴的半雪完成签到 ,获得积分10
28秒前
大橙子发布了新的文献求助10
29秒前
meng完成签到,获得积分10
30秒前
31秒前
31秒前
科研韭菜完成签到 ,获得积分10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022